chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills) and PYREXIA (Fever) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011320A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced CHILLS (Chills) and PYREXIA (Fever). At the time of the report, CHILLS (Chills) and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2021, Body temperature: 101.2 (Inconclusive) Degrees Fahrenheit.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Influenza vaccine administered at well checkup 1/9/08 about 3:30pm.  Mom reports he became very fussy that night and had barky cough.  Neb treatment with Albuterol no help.  Next AM, more panic and screaming, seen in office by Dr., did have big inner ear infection but in more distress than expected, saying "it's an emergency", "I can't breath" and in tears.  Difficult to console in office.  Given ear drops (acralfan), Motrin, and then Benadryl, finally about 10 min after Benadryl he fell asleep.  Patient seemed to be in a panic, which is out of character for him.  Sent home on Zithromax for ear infection and Benadryl every 6 hours.  (Exam showed no hives, no swelling, no wheezing, no respiratory distress but very panicked.)
mom reports p/vax lt mid-thigh leg started to swell several hrs later & by 6PM lt leg was swollen & fire red from inject site to knee, including the entire knee joint & was unable to bend knee; mom gave APAP, put ice on swollen area; temp
Body aches; rash is now over most of her torso but a lite rash; One degree fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches), RASH (rash is now over most of her torso but a lite rash) and PYREXIA (One degree fever) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     The patient's past medical history included Laparoscopic surgery on 08-Apr-2021.    On 12-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Apr-2021, the patient experienced PAIN (Body aches), RASH (rash is now over most of her torso but a lite rash) and PYREXIA (One degree fever). At the time of the report, PAIN (Body aches), RASH (rash is now over most of her torso but a lite rash) and PYREXIA (One degree fever) outcome was unknown.            Treatment information was not provided. No concomitant medications were reported.
within a 1/2 hr...she started with diarrhea redding around injection site that has spread to areas on upper arm
Client reported feeling nervous prior to receiving vaccine, but informed the vaccinator that she wanted to continue with receiving the vaccination.  About 30 seconds after receiving the vaccine, she reported feeling flushed and dizzy.  Vaccinator assisted her to the side to sit on the ground.  Vitals signs were taken, 15:18: BP 170/110, HR 120, T: 97.3. Client appeared sweaty and skin felt clammy.  Client was provided water and Powerade and encouraged to drink and rest.  Safety and EMS on site were notified and responded.  911 was not activated.  BP was elevated and client reported that she did not know her normal BP, but has heard from her doctor that it is high, but not prescribed daily medication for maintenance.  She reported taking metoprolol as needed.  Vital signs: 15:22: BP 170/110, HR 100; 15:27: BP 164/110; 15:30 (standing): BP 160/114, HR 130; 15:53: BP 140/108, HR 100.  Client continued to rest and was offered additional water, Powerade, and snacks which were declined.  She reported feeling better, vital signs were stable/consistent and she was no longer sweaty and clammy.  She declined an escort back to her car and was released from the vaccination area at 16:10.
Case number PHEH2013US017041 is an initial spontaneous report received from a consumer on 08 Aug 2013 with a follow up information received from the physician on 27 Aug 2013. This report refers to a 19-years-old female patient. It was reported that she was healthy. Her medical history included allergies and concomitant medications were not reported. Her vaccination status was up to date and she was previously administered MENACTRA (other manufacturer, batch number: not reported) which was well tolerated. She was vaccinated with MENVEO (batch  number: not reported) at a dose of 0.5 ml intramuscularly in the right arm on 05 Aug 2013. She also concomitantly received GARDASIL (other manufacturer, batch number: not reported) in left arm on 05 Aug 2013. It was reported that on the same day evening, the injection site of her right arm was red, warm to touch and swollen about 2 inches oval shaped. It was reported that it hurt to touch the vaccination site, but she was able to move her arm. The outcome of the event was reported as complete recovery. No further information was provided. Follow up information received from physician on 27 Aug 2013: Physician was added as primary reporter, patient demographics (height and weight), medical history and vaccination history, dose of vaccine and event outcome updated.
The patient visited due to a vaccine reaction with nausea, headaches, limb pain, and abdominal symptoms. No anomalies from the internal med. point of view (clinical and laboratory), so that the patient was referred to a gynecologic examination due to pregnancy. This examination did not show any anomalies. The treatment remained under outpatient conditions.
One week after the vaccination I woke up and felt a burning tingling sensation on my right side of my torso. As the day went on it moved up to my shoulders, arm and neck. The next day it was up to my head and it was burning. The following day it moved down to my thigh. The next day it moved down to my toes. After about 4-5 days I made a Dr. appt and she told me it sounded like shingles. There was nothing visible on my skin and I've never had shingles before. She did blood work and urinalysis and she put me on gabapentin. 300mg 2x day. It was a 90 day supply. It helped a little bit to where the tingling was concentrated around my waist. Once I ran out of the medication the pain returned. She gave me another refill and that helped a little but once that ran out she suggested I see a neurologist. I did not get a chance to see a neurologists so I have made due without any medication. It is now down to about a 6" wide strip from my armpit to just below my waist.
pt recv vax 1MAY96 & 8MAY96 pt devel 17 chicken pox cells;By 10MAY96 the number of lesions inc to 73;no further details were provided;
My ankle and leg started swell. I was seen by a doctor and discovered my lung and heart was fine. My doctor stated my age cause with vaccine caused my legs and ankle to swell.
Vomiting; Massive Migraine; Pain in neck; Dizziness; Headache; Nausea; Made me sick; This is a spontaneous report from a contactable consumer (Patient). A 51-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Lot Number: EW0167; Expiration Date: 31Aug2021), via an unspecified route of administration on 20May2021 at 16:30 (at the age of 51-year-old) as 1st dose, single dose in right arm for COVID-19 immunisation at Public Health Department. The patient's medical history included arthritis and gout. The patient had known allergies to amoxicillin. Concomitant medications within 2 weeks of vaccination included allopurinol (ALLOPURINOL) taken for gout, celecoxib (CELEBREX) taken for arthritis, gabapentin (GABAPENTIN), and buprenorphine (BUPRENORPHINE). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 20May2021 at 22:30, after the first shot of vaccine, the patient experienced massive migraine, pain in neck, dizziness, vomiting, headache, and nausea. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Treatment medication included Sumatriptan Succinate 50mg and then 100 mg (Manufacturer: Aurobindo). On an unspecified date in May2021, the patient reported that the Pfizer shot had made her sick. The patient underwent lab tests and procedures on Apr2021 which included blood test: unknown results and patient had several blood test over the last month. The patient had no COVID prior vaccination and was not tested COVID post vaccination. The clinical outcome of the event made me sick was unknown and clinical outcome of all other events was not resolved.
A report has been received from a Health Professional concerning a 1 year old, Male subject, who had been receiving FLUMIST quadrivalent, (intranasal), 0.2 Millilitres. The patient's concurrent disease(s) included thyroid, diabetes mellitus and high blood pressure. Family history included Eczema, FLUMIST quadrivalent (intranasal) started on 24-Sep-2015. The patient who was 1 year old was administered FLUMIST on 24-Sep-2015. No wheezing. The outcome of the event of administered to 1 year old and was administered FLUMIST, is 1 year old is unknown. The reporter's description of the event(s) was as follows: No known medical problems. Family history of eczema, DM, HTN, thyroid. The report was considered to be non-serious.
Nausea, severe headache, very dizzy, started 22 hours after Very flushed, fever 100.6 at 28 hours after
Hours after the injection, soreness at the spot of the injection that has subsuded. Sore lymph nodes beginning on the side of the injection around 3pm the next day. 100.3 fever two nights after the injection.
Horrible Headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer), for COVID-19 immunization. The following information was reported: HEADACHE (non-serious), outcome "unknown", described as "Horrible Headache".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
dose 1 and dose 2 though I had a mild fever.; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (dose 1 and dose 2 though I had a mild fever.) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (dose 1 and dose 2 though I had a mild fever.). At the time of the report, PYREXIA (dose 1 and dose 2 though I had a mild fever.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication was reported. No concomitant medication was reported.   This case was linked to MOD-2022-512781, MOD-2022-512787 (Patient Link).
Patient described swelling in nasal passages shortly after receiving vaccine, which made it hard to breathe. He then started to feel warm in his head and upper chest with continued shortness of breath. Later that evening he felt nauseous but was not able to vomit. He checked his temperature and had a slight fever this morning. He called the poison control center that evening but they did not instruct him to take any action.
Swelling, rash, redness at injection site - spread to under arm and lymph region near left breast. Muscle pain at injection site. Stomach pain and upset.
Sudden onset of cardboard-like taste 1 hour after injection. Full taste and smell senses remain. Taste has persisted for greater than 24 hours now.
Tachypnea, Palpitations, HYPERtension, Angina, Lip numbness, Diaphoresis, Anxious, scratchy throat Narrative:
COVID 19; COVID 19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 09Apr2021 as dose 1, single (Lot number: EW0153), in right arm, on 30Apr2021 as dose 2, single (Lot number: EW0153), in right arm and on 20Nov2021 as dose 3 (booster), single (Lot number: EW0183) at the age of 34 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Environmental allergies" (unspecified if ongoing); "Skin issues" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Amoxicillin, reaction(s): "Known allergies: Amoxicillin".  The following information was reported: VACCINATION FAILURE (medically significant) with onset 27Apr2022, outcome "unknown", COVID-19 (medically significant) with onset 27Apr2022, outcome "recovered with sequelae" (16May2022) and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (30Apr2022) Negative, notes: Tested negative on antigen on 30Apr; (08May2022) Negative, notes: tested negative on antigen before I left; (09May2022) Positive, notes: Tested positive on a PCR and two antigen tests on 9May; (16May2022) Positive, notes: Continued to test positive on antigen tests; (30Apr2022) Positive, notes: Tested negative on antigen on 30Apr, but positive on PCR; (05May2022) Negative, notes: Tested negative on PCR on antigen tests on 5May; (09May2022) Positive, notes: Tested positive on a PCR and two antigen tests on 9May. Therapeutic measures were taken as a result of covid-19.  Clinical course: The patient received treatment with anti-viral product brand paxlovid, treatment start date 30apr2022, treatment stop date 04may2022. The patient got Covid from an outdoor event on 27Apr. Symptoms started on 29Apr. Tested negative on antigen on 30Apr, but positive on PCR. Started Paxlovid on 30Apr. Tested negative on PCR on antigen tests on 5May. Was distanced and masked up until my flight on 8May,  tested negative on antigen before she left. Tested positive on a PCR and two antigen tests on 9May. Continued to test positive on antigen tests through 16May. Symptoms changed from round one to round two. Round one: mostly sore throat with some cough, fever, chills, diarrhea, nausea, brain fog, body aches. Round two: mostly nasal congestion with some diarrhea, sore throat, nausea.
Dizzy and nausea at 6 pm the day of the vaccination. Sore throat in morning next day; then fever for 4 days (102-103.5); cough; headache; body aches.
J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 3/14/2021 HTN (HYPERTENSION) J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 3/14/2021 HYPERNATREMIA
Initial misuse report received from a healthcare professional on 15 May 2013. A patient received the powder portion of the ACTHIB reconstituted with sterile water (diluents for MMR) rather than the diluents that comes with the ACTHIB. (No information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
red blotches on left arm; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (red blotches on left arm) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RASH MACULAR (red blotches on left arm). At the time of the report, RASH MACULAR (red blotches on left arm) outcome was unknown.            Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) for events was not applicable.  No concomitant medications were reported. No treatment information was provided.
worst seizure; First Pfizer Covid Shot on 17Mar2021# Second Pfizer Covid Shot on 31Mar2021; This is a spontaneous report from a non-contactable consumer (parent of patient). This report is for the second dose. A 16-year-old non-pregnant female patient received BNT162B2(PFIZER BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration, administered in left arm on 31Mar2021 (Batch/Lot Number: ER8727) as single dose for COVID-19 immunisation. Relevant medical history includes catamenial epilepsy and attention deficit hyperactivity disorder (ADHD). Patient had no other vaccines in 4 weeks. Patient had no known allergies. Patient had not had COVID prior to vaccination. Concomitant medications included levetiracetam (KEPPRA) taken at 1000 mg twice daily to help control seizures, start and stop date were not reported and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) taken for an unspecified indication, start and stop date were not reported. Patient historically took first dose of Pfizer BNT162B2 (Lot number EN6206) on the left arm at age 16 years on 17Mar2021 at 10:30AM for COVID-19 immunisation and experienced worst seizures. Reporter's daughter has been diagnosed with catamenial epilepsy, and has been taking 1000 mg KEPPRA twice daily to help control seizures. The shortest duration between seizures was approximately 1 month, and that was before her epilepsy diagnosis and starting on the KEPPRA. She has recently suffered a cluster of seizures which is atypical for her. Last night, reporter read an article about some women starting their periods after years of not having it soon after receiving the COVID vaccine, so reporter looked back at her daughter's seizure record and noticed a potential link.Patient had her first Pfizer COVID Shot on 17Mar2021, and she experienced her worst seizure ever on 27Mar2021 (10 days after COVID vaccine). On 31Mar2021, patient had her second Pfizer COVID Shot and she experienced her second worst seizure ever on 10Apr2021 (again 10 days after the second COVID vaccine. Again, her daughter has never had seizures occur in such a short duration, with the minimum time between seizures being one month. The adverse reaction resulted in doctor or other healthcare professional office/clinic visit. Patient was treated for the event which is increase in KEPPRA dose to 1250 mg. Patient had not been tested with COVID-19 post vaccination. Vaccination facility was at a public health department. The outcome was unknown.   No follow up attempts are possible. No further information is expected.
While sitting on mother's lap during administration of varicella vaccine, client arched back, tensed both arms/hands, became pale and unresponsive.  Loss of bladder control.  Episode lasted approx. 15-20 seconds.  Post episode, client oriented to person, place and time; sat up, ate and drank; talked with family members and RN.  This nurse referred mother to PCP or other health care provider for follow-up evaluation.  Client walked out of clinic -- smiling and chatting -- in the company of her family.
Report 20010099331 described herpes zoster in a female of unspecified age who received hep B. Reportedly, the vaccinee had no allergies and took no concomitant medications. Her medical history included arthritis. On 04/13/2001, the vaccinee received her first dose of Engerix-B. three days later, on 04/16/2001, she was diagnosed with herpes zoster. As of 04/18/2001, the event was unresolved.
Rash Narrative: rash around injection site 7x7.5cm up to 8 days later
Pt went to the school clinic at approx 145 pm c/o itching. Secretary alerted the nurse who then saw that the pt's face was reddened with hives. Pt c/o abdominal discomfort and was assisted to the bathroom. (911 was alerted when the nurses were located) pt was given 0.4mg Epi SQ, then 40 mg BENADRYL IM, assisted to cot feet elevated, BP 110/68, pulse ox 98%, pulse 120, temp 97.8, meds were given at 155pm -157pm, squad arrived, pt transported to ER, pt was alert and oriented during event. Pt attended school next day.
reactions from 1st dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (reactions from 1st dose of the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (reactions from 1st dose of the vaccine). At the time of the report, VACCINATION COMPLICATION (reactions from 1st dose of the vaccine) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Concomitant medication were not reported by the reporter. Treatment details was not reported by the reporter.
Administered Tdap and Gardisil, pt.'s head dropped, was unresponsive, arms and legs drew up in seizure-like activity, pt. was incontinent of urine, pt. regained consciousness after several seconds.
swelling and hard lump at the injection site, redness, and heat; swelling and hard lump at the injection site; at the injection site redness; at the injection site heat; hard lump at the injection site; hard lump at the injection site; Initial information received on 23-Sep-2019 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a patient (reported as 4) who experienced swelling and hard lump at the injection site, redness, and heat (vaccination site inflammation, vaccination site mass, vaccination site induration, vaccination site swelling, vaccination site erythema and vaccination site warmth), while he/she received vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 18-SEP-2019, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE lot number not reported via unknown route and unknown site.  On an unknown date, the patient had swelling and hard lump at the injection site, redness, and heat (vaccination site inflammation, vaccination site mass, vaccination site induration, vaccination site swelling, vaccination site erythema and vaccination site warmth) (Unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  Lab data was not reported.  Final diagnosis was vaccination site inflammation, vaccination site mass, vaccination site induration, vaccination site swelling, vaccination site erythema and vaccination site warmth.   Patient was recommended with ice the injection site, take Motrin and Benadryl  The patient outcome was reported as unknown for vaccination site inflammation, vaccination site mass, vaccination site induration, vaccination site swelling, vaccination site erythema and vaccination site warmth.  Information on the batch number is requested.  List of document held by sender: none.